Hyperlipoproteinemia: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 56: Line 56:
! rowspan="3" |Diseases
! rowspan="3" |Diseases
! rowspan="3" |Mode of Inheritance
! rowspan="3" |Mode of Inheritance
! colspan="6" |Laboratory Findings
! colspan="8" |Laboratory Findings
! rowspan="3" |Other Findings
! rowspan="3" |Other Findings
! rowspan="3" |Management
! rowspan="3" |Management
Line 63: Line 63:
|-
|-
! colspan="5" |Lipid Profile
! colspan="5" |Lipid Profile
! rowspan="2" |Genetic mutations
! colspan="3" |Other Laboratory Findings
|-
|-
!Total Cholesterol
!Total Cholesterol
Line 70: Line 70:
!Triglycerides
!Triglycerides
!Plasma Appearance
!Plasma Appearance
!Chylomicrons
!VLDL
!Genetic mutations
|-
|-
| rowspan="6" |'''Primary Hyperlipoprotenemia'''
| rowspan="6" |'''Primary Hyperlipoprotenemia'''
Line 79: Line 82:
|'''↑↑↑↑'''
|'''↑↑↑↑'''
|Creamy
|Creamy
|
|
|LPL gene mutation
|LPL gene mutation
|Chylomicrons
|Chylomicrons


Elevated
Elevated
|Treatment for hyperlipoproteinemia type 1 is intended to control blood triglyceride levels with a very low-fat diet
|
|<nowiki>-Recurrent Pancreatitis</nowiki>
|<nowiki>-Recurrent Pancreatitis</nowiki>


Line 90: Line 95:
|-
|-
|Type IIA
|Type IIA
|
|
|
|
|
|
Line 103: Line 110:
|-
|-
|Type IIB
|Type IIB
|
|
|
|
|
|
Line 116: Line 125:
|-
|-
|Type III
|Type III
|
|
|
|
|
|
Line 129: Line 140:
|-
|-
|Type IV
|Type IV
|
|
|
|
|
|
Line 142: Line 155:
|-
|-
|Type V
|Type V
|
|
|
|
|
|
Line 156: Line 171:
| rowspan="10" |'''Secondary Hyperlipoprotenemia'''
| rowspan="10" |'''Secondary Hyperlipoprotenemia'''
|Diabetes Mellitus
|Diabetes Mellitus
|
|
|
|
|
|
Line 169: Line 186:
|-
|-
|Alcohol Abuse
|Alcohol Abuse
|
|
|
|
|
|
Line 182: Line 201:
|-
|-
|Estrogen Therapy
|Estrogen Therapy
|
|
|
|
|
|
Line 195: Line 216:
|-
|-
|Glucocorticoid therapy
|Glucocorticoid therapy
|
|
|
|
|
|
Line 208: Line 231:
|-
|-
|Renal Disease
|Renal Disease
|
|
|
|
|
|
Line 221: Line 246:
|-
|-
|Obesity
|Obesity
|
|
|
|
|
|
Line 234: Line 261:
|-
|-
|High-fat diet
|High-fat diet
|
|
|
|
|
|
Line 247: Line 276:
|-
|-
|Poor physical activity
|Poor physical activity
|
|
|
|
|
|
Line 260: Line 291:
|-
|-
|Paraproteinemic disorders
|Paraproteinemic disorders
|
|
|
|
|
|
Line 273: Line 306:
|-
|-
|Hypothyroidism
|Hypothyroidism
|
|
|
|
|
|

Revision as of 21:38, 8 November 2016

Lipoprotein Disorders Main Page

Hyperlipoproteinemia Microchapters

Hypercholesterolemia Patient Information

Hypertriglyceridemia Patient Information

Overview

Classification

Familial hyperchylomicronemia
Familial hypercholesterolemia
Familial combined hyperlipidemia
Dysbetalipoproteinemia
Primary hypertriglyceridemia
Mixed hyperlipoproteinemia

Differential Diagnosis

Screening

ACC/AHA Guideline Recommendations

Summary

Treatment

Major recommendations for statin therapy

Therapeutic response to statin therapy

Blood cholesterol LDL and non-HDL treatment goals

Treatment in heart failure and hemodialysis

Primary prevention

Secondary prevention

Intensity of statin therapy in primary and secondary prevention

Safety Recommendations

Guideline on Lifestyle Management

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Synopsis

Hyperlipoproteinemia Synonyms Problems Labs description Treatment
Type I Buerger-Gruetz syndrome, primary hyperlipoproteinaemia, or familial hyperchylomicronemia Decreased lipoprotein lipase (LPL) or altered ApoC2 Elevated chylomicrons Diet control
Type IIa Polygenic hypercholesterolaemia or familial hypercholesterolemia LDL receptor deficiency Elevated LDL only Bile acid sequestrants, statins, niacin
Type IIb Combined hyperlipidemia Decreased LDL receptor and increased ApoB Elevated LDL, VLDL and triglycerides Statins, niacin, gemfibrozil
Type III Familial Dysbetalipoproteinemia Defect in ApoE synthesis Increased IDL Drug of choice: Gemfibrozil
Type IV Endogenous Hyperlipemia Increased VLDL production and decreased elimination Increased VLDL Drug of choice: Niacin
Type V Familial Hypertriglyceridemia Increased VLDL production and decreased LPL Increased VLDL and chylomicrons Niacin, gemfibrozil

Differential Diagnosis

Diseases Mode of Inheritance Laboratory Findings Other Findings Management Complications Prognosis
Lipid Profile Other Laboratory Findings
Total Cholesterol LDL HDL Triglycerides Plasma Appearance Chylomicrons VLDL Genetic mutations
Primary Hyperlipoprotenemia Type I Autosomal Recessive Normal or Normal Normal ↑↑↑↑ Creamy LPL gene mutation Chylomicrons

Elevated

-Recurrent Pancreatitis

-Rarely life threatening

Good
Type IIA
Type IIB
Type III
Type IV
Type V
Secondary Hyperlipoprotenemia Diabetes Mellitus
Alcohol Abuse
Estrogen Therapy
Glucocorticoid therapy
Renal Disease
Obesity
High-fat diet
Poor physical activity
Paraproteinemic disorders
Hypothyroidism

Classification

 
 
 
 
 
 
 
 
 
 
 
 
 
Hyperlipoproteinemia
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Type I:
Familial hyperchylomicronemia
 
 
Type II
 
Type III:
Dysbetalipoproteinemia
 
Type IV:
Primary hypertriglyceridemia
 
Type V:
Mixed hyperlipoproteinemia
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Type A:
Familial hypercholesterolemia
 
Type B:
Familial combined hyperlipidemia
 

References

Template:WH Template:WS